Clinical Trials
12
Active:10
Completed:0
Trial Phases
3 Phases
Phase 1:9
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (75.0%)Phase 3
2 (16.7%)Phase 2
1 (8.3%)Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Device: Gereic Dry Powder Inhaler
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06274801
- Locations
- 🇺🇸
Stanford Healthcare, Stanford, California, United States
🇺🇸The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Phase 3
Active, not recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05934526
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Valley Advanced Lung Diseases Institute, Fresno, California, United States
🇺🇸UC San Diego Medical Center (La Jolla), La Jolla, California, United States
News
No news found